SuperworthEndovia Health Sciences revenue EDVA
Sales by quarter and over the last twelve months, from 2012.
- Last 12 months, to Jun 30, 2025
- $2M
- Latest quarter, Q2 FY25
- $0
- −100% on a year earlier
- Fiscal year 2024
- $4.2M
- −78% on the year before
Endovia Health Sciences' revenue was $2M over the twelve months to Jun 30, 2025, down 81% on a year earlier.
In its latest quarter, Q2 FY25, it was $0, down 100% on the same quarter a year before.
Over the five fiscal years to FY2024 it grew 46% a year on average.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2024 | $4.2M | −78% |
| FY2023 | $18.9M | +4% |
| FY2022 | $18.1M | +60% |
| FY2021 | $11.3M | +392% |
| FY2020 | $2.3M | +273% |
| FY2019 | $616.4K | −53% |
| FY2018 | $1.3M | +46% |
| FY2017 | $895.3K | −15% |
| FY2016 | $1M | +17% |
| FY2015 | $897.3K | +55% |
| FY2014 | $580.5K | +22% |
| FY2013 | $475.3K | +54% |
| FY2012 | $308.7K | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY25 | $0 | −100% | $2M | |
| Q1 FY25 | $438.3K | −72% | $3.1M | |
| Q4 FY24 | $585.9K | −78% | $4.2M | |
| Q3 FY24 | $981.9K | −81% | $6.3M | |
| Q2 FY24 | $1M | −80% | $10.4M | |
| Q1 FY24 | $1.5M | −74% | $14.6M | |
| Q4 FY23 | $2.7M | −44% | $18.9M | |
| Q3 FY23 | $5.1M | +6% | $21M | |
| Q2 FY23 | $5.2M | +15% | $20.7M | |
| Q1 FY23 | $5.8M | +48% | $20M | |
| Q4 FY22 | $4.8M | +56% | $18.1M | |
| Q3 FY22 | $4.9M | +72% | $16.4M |
Against its peers
Companies in Beverages - Non-Alcoholic nearest Endovia Health Sciences' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| EDVAEndovia Health Sciences | n/m | |
| IPSTIP Strategy | $10.7M | +40% a year |
| AMSSAmass Brands | n/m | |
| YHCLQR House | $1.2M | −50% a year |
| REEDReed'S | $29.1M | −19% a year |
| WVVIWillamette Valley Vineyards | $37.8M | −2% a year |
| SRXHSRX Global | n/m | |
| BUDABuda Juice | n/m | |
| ZVIAZevia PBC | $169.8M | +7% a year |
| BRCCBRC | $429.7M | +10% a year |
| SUJASuja Life | n/m | |
| Peer median | $33.4M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Endovia Health Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.